NCT05416359 - Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2024

Conditions

Advanced Malignant Tumor

Interventions

DRUG

TQB3915 tablets

TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.

Trial Locations (3)

210029

RECRUITING

First Affiliated Hospital with Nanjin Medical University (Jiangsu Province Hospital), Nanjing

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

510060

RECRUITING

Sun Yat-Sen University Cancer Canter, Guangzhou